Journal
FEBS LETTERS
Volume 582, Issue 1, Pages 81-89Publisher
WILEY
DOI: 10.1016/j.febslet.2007.11.018
Keywords
AMP-activated protein kinase; metabolic syndrome; diabetes; metformin; thiazolidinedione; ventricular pre-excitation
Funding
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
Obesity, type 2 diabetes and the metabolic syndrome are disorders of energy balance, which the AMP-activated protein kinase (AMPK) regulates both at the cellular and whole body levels. AMPK switches cells from an anabolic state where nutrients are taken up and stored, to a catabolic state where they are oxidized. Drugs that activate AMPK indirectly (metformin and thiazolidinediones) are now the mainstay of treatment for type 2 diabetes, but more direct AMPK activators may have fewer side effects. However, activating mutations in AMPK can cause heart disease, and it will be important to look for adverse effects in the heart. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available